Subscriber's Home Page – Click Here

Click Here To PrintIn August 2019, the New England Journal of Medicine published a research article1 titled “An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes”. There were 76 participants in the research, 55 of whom were 18 years old or younger. Research “subjects” (a word commonly used in place of “participants”)...

This content is for subscribers only.
Click Here To Login or Subscribe!